TLRY
Price
$1.13
Change
-$0.10 (-8.13%)
Updated
Nov 13 closing price
Capitalization
1.27B
59 days until earnings call
Intraday BUY SELL Signals
YCBD
Price
$0.74
Change
-$0.03 (-3.90%)
Updated
Nov 13 closing price
Capitalization
6.58M
Intraday BUY SELL Signals
Interact to see
Advertisement

TLRY vs YCBD

Header iconTLRY vs YCBD Comparison
Open Charts TLRY vs YCBDBanner chart's image
Tilray Brands
Price$1.13
Change-$0.10 (-8.13%)
Volume$55.04M
Capitalization1.27B
CBDMD
Price$0.74
Change-$0.03 (-3.90%)
Volume$115.59K
Capitalization6.58M
TLRY vs YCBD Comparison Chart in %
View a ticker or compare two or three
VS
TLRY vs. YCBD commentary
Nov 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is TLRY is a Hold and YCBD is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 14, 2025
Stock price -- (TLRY: $1.23 vs. YCBD: $0.77)
Brand notoriety: TLRY: Notable vs. YCBD: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: TLRY: 47% vs. YCBD: 2%
Market capitalization -- TLRY: $1.27B vs. YCBD: $6.58M
TLRY [@Pharmaceuticals: Generic] is valued at $1.27B. YCBD’s [@Pharmaceuticals: Generic] market capitalization is $6.58M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

TLRY’s FA Score shows that 0 FA rating(s) are green whileYCBD’s FA Score has 1 green FA rating(s).

  • TLRY’s FA Score: 0 green, 5 red.
  • YCBD’s FA Score: 1 green, 4 red.
According to our system of comparison, both TLRY and YCBD are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

TLRY’s TA Score shows that 2 TA indicator(s) are bullish while YCBD’s TA Score has 3 bullish TA indicator(s).

  • TLRY’s TA Score: 2 bullish, 7 bearish.
  • YCBD’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, YCBD is a better buy in the short-term than TLRY.

Price Growth

TLRY (@Pharmaceuticals: Generic) experienced а -3.91% price change this week, while YCBD (@Pharmaceuticals: Generic) price change was -5.48% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +1.08%. For the same industry, the average monthly price growth was -3.24%, and the average quarterly price growth was +32.16%.

Reported Earning Dates

TLRY is expected to report earnings on Jan 12, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (+1.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TLRY($1.27B) has a higher market cap than YCBD($6.58M). TLRY YTD gains are higher at: -7.519 vs. YCBD (-74.197). YCBD has higher annual earnings (EBITDA): 163K vs. TLRY (-2.11B). TLRY has more cash in the bank: 265M vs. YCBD (1.06M). YCBD has less debt than TLRY: YCBD (963K) vs TLRY (324M). TLRY has higher revenues than YCBD: TLRY (831M) vs YCBD (19M).
TLRYYCBDTLRY / YCBD
Capitalization1.27B6.58M19,292%
EBITDA-2.11B163K-1,296,906%
Gain YTD-7.519-74.19710%
P/E RatioN/A1.45-
Revenue831M19M4,374%
Total Cash265M1.06M25,000%
Total Debt324M963K33,645%
FUNDAMENTALS RATINGS
TLRY vs YCBD: Fundamental Ratings
TLRY
YCBD
OUTLOOK RATING
1..100
6067
VALUATION
overvalued / fair valued / undervalued
1..100
52
Fair valued
51
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
4091
P/E GROWTH RATING
1..100
921
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

YCBD's Valuation (51) in the Other Consumer Services industry is in the same range as TLRY (52) in the Biotechnology industry. This means that YCBD’s stock grew similarly to TLRY’s over the last 12 months.

YCBD's Profit vs Risk Rating (100) in the Other Consumer Services industry is in the same range as TLRY (100) in the Biotechnology industry. This means that YCBD’s stock grew similarly to TLRY’s over the last 12 months.

YCBD's SMR Rating (98) in the Other Consumer Services industry is in the same range as TLRY (98) in the Biotechnology industry. This means that YCBD’s stock grew similarly to TLRY’s over the last 12 months.

TLRY's Price Growth Rating (40) in the Biotechnology industry is somewhat better than the same rating for YCBD (91) in the Other Consumer Services industry. This means that TLRY’s stock grew somewhat faster than YCBD’s over the last 12 months.

YCBD's P/E Growth Rating (1) in the Other Consumer Services industry is significantly better than the same rating for TLRY (92) in the Biotechnology industry. This means that YCBD’s stock grew significantly faster than TLRY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
TLRYYCBD
RSI
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
79%
Declines
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
TLRY
Daily Signal:
Gain/Loss:
YCBD
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
WWD274.034.88
+1.81%
Woodward
STHO7.770.06
+0.78%
Star Holdings
CHEF61.750.17
+0.28%
Chefs' Warehouse (The)
CASS41.770.02
+0.05%
Cass Information Systems
JEM0.29-0.01
-2.28%
707 Cayman Holdings Limited

TLRY and

Correlation & Price change

A.I.dvisor indicates that over the last year, TLRY has been closely correlated with SNDL. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if TLRY jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TLRY
1D Price
Change %
TLRY100%
-4.65%
SNDL - TLRY
76%
Closely correlated
-3.24%
OGI - TLRY
64%
Loosely correlated
-1.83%
CRON - TLRY
64%
Loosely correlated
+0.79%
CGC - TLRY
63%
Loosely correlated
-0.83%
ACB - TLRY
61%
Loosely correlated
-0.44%
More

YCBD and

Correlation & Price change

A.I.dvisor indicates that over the last year, YCBD has been loosely correlated with TLRY. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if YCBD jumps, then TLRY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To YCBD
1D Price
Change %
YCBD100%
-3.72%
TLRY - YCBD
40%
Loosely correlated
-4.65%
ACB - YCBD
39%
Loosely correlated
-0.44%
OGI - YCBD
31%
Poorly correlated
-1.83%
CRON - YCBD
30%
Poorly correlated
+0.79%
CGC - YCBD
29%
Poorly correlated
-0.83%
More